Skip to content

Current ratio at other companies

Baxter International logo
Baxter InternationalBAX
1.9×-0.2×
PTH
Pelthos Therapeutics Inc.PTHS
2.8×+2.6×
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
2.6×+0.4×
BridgeBio Pharma logo
BridgeBio PharmaBBIO
1.5×-3.0×
RFL
Rafael Holdings, Inc.RFL
3.2×-0.7×
Opko Health logo
Opko HealthOPK
3.6×+1.1×

Other financials

Income statement

See full
Revenue$9.1M-22.0%
Gross profit$7.2M-30.0%
Operating income-$3.1M-342%
Net income-$3.3M-362%
EPS (diluted)-$0.22-375%

Balance sheet

See full
Cash & equivalents$11.0M-27.1%
Total debt$4.8M-7.1%
Total equity$21.6M-24.5%
Total assets$71.0M+1.5%

Cash flow

See full
Operating cash flow$387.0K-90.1%
CapEx--100%
Free cash flow$387.0K-89.9%

Valuation

See full
Market cap$97.09M+142%
Enterprise value$90.91M+212%
P/S2.3×+1.4×

Profitability

See full
Gross margin82.9%-1.4pp
Operating margin-17.2%-125pp
Net margin-17.6%-103pp
FCF margin3.3%

Returns & leverage

See full
Return on equity-29.4%-86.3pp
Debt / equity0.2×0.0×

Where this comes from

Calculated from Cumberland Pharmaceuticals’s reported figures.

Based on the most recent quarter.

The official record: Cumberland Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cumberland Pharmaceuticals's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cumberland Pharmaceuticals's current ratio?
Cumberland Pharmaceuticals (CPIX) reported current ratio of 1× in Q1 2026.
How has Cumberland Pharmaceuticals's current ratio changed year-over-year?
Cumberland Pharmaceuticals's current ratio decreased by 23.9% year-over-year, from 1.2× to 1×.
What is the long-term trend for Cumberland Pharmaceuticals's current ratio?
Over 5 years (2020 to 2025), Cumberland Pharmaceuticals's current ratio has grown at a -12.3% compound annual growth rate (CAGR), from 1.9× to 1×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.